Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is known for its innovative approach to treating conditions like depression and migraines. In a competitive landscape, Axsome stands out with its unique drug pipeline and strategic partnerships.
On January 7, 2026, Herriot Tabuteau, the CEO and a significant shareholder of Axsome, sold 31,261 shares at $170.38 each. This transaction reduced his holdings to 7,229 shares. This move follows a similar transaction by Director Mark Saad, who sold 37,577 shares at $165.18 each on December 31st, reducing his ownership by 78.98% to 10,002 shares.
Axsome's stock opened at $178.69 recently, with a current price of $170.69, reflecting a slight decrease of 0.69%. The stock has traded between $168.02 and $173.73 today. Over the past year, it has seen a low of $79.19 and a high of $184.40, indicating significant volatility.
The company has a market capitalization of approximately $8.60 billion. Despite a negative price-to-earnings (P/E) ratio of -38.26, the price-to-earnings-growth ratio stands at 16.17. Axsome's financial health is supported by a debt-to-equity ratio of 1.66, a quick ratio of 1.50, and a current ratio of 1.57, suggesting a stable liquidity position.
